High-Risk Cardiac Disease in Pregnancy: Part II

Journal of the American College of Cardiology

Volumn 68, Issue 5, 2016, Pages 502-516

  Elkayam, Uri ^a   Goland, Sorel ^b   Pieper, Petronella G ^c   Silverside, Candice K ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

cardiomyopathies; congenital; heart defects; hypertension; Marfan syndrome; post partum period; pulmonary; Turner syndrome

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN;

AORTA DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL FEATURE; COMORBIDITY; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; CYANOTIC HEART DISEASE; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; FOLLOW UP; FONTAN PROCEDURE; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; HUMAN; LONG TERM CARE; MARFAN SYNDROME; MATERNAL CARE; MATERNAL MORBIDITY; MATERNAL MORTALITY; PATIENT COUNSELING; PERIPARTUM CARDIOMYOPATHY; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW;

EID: 84978828665     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.05.050     Document Type: Review

References (115)

1. 1 Curtis, S.L., Marsden-Williams, J., Sullivan, C., et al. Current trends in the management of heart disease in pregnancy. Int J Cardiol 133 (2009), 62–69.
2. 2 Siu, S.C., Sermer, M., Colman, J.M., et al., for the Cardiac Disease in Pregnancy (CARPREG) Investigators. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 104 (2001), 515–521.
3. 3 Roos-Hesselink, J.W., Ruys, T.P., Stein, J.I., et al., for the ROPAC Investigators. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J 34 (2013), 657–665.
4. 4 Drenthen, W., Boersma, E., Balci, A., et al., for the ZAHARA Investigators. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 31 (2010), 2124–2132.
5. 5 Drenthen, W., Pieper, P.G., Roos-Hesselink, J.W., et al., for the ZAHARA Investigators. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 49 (2007), 2303–2311.
6. 6 Fesslova, V.M., Villa, L., Chessa, M., et al. Prospective evaluation from single centre of pregnancy in women with congenital heart disease. Int J Cardiol 131 (2009), 257–264.
7. 7 Ruys, T.P., Roos-Hesselink, J.W., Hall, R., et al. Heart failure in pregnant women with cardiac disease: data from the ROPAC. Heart 100 (2014), 231–238.
8. 8 Ford, A.A., Wylie, B.J., Waksmonski, C.A., et al. Maternal congenital cardiac disease: outcomes of pregnancy in a single tertiary care center. Obstet Gynecol 112 (2008), 828–833.
9. 9 Kovacs, A.H., Harrison, J.L., Colman, J.M., et al. Pregnancy and contraception in congenital heart disease: what women are not told. J Am Coll Cardiol 52 (2008), 577–578.
10. 10 Balci, A., Sollie-Szarynska, K.M., van der Bijl, A.G., et al., for the ZAHARA-II Investigators. Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. Heart 100 (2014), 1373–1381.
11. 11 Regitz-Zagrosek, V., Blomstrom Lundqvist, C., Borghi, C., et al. ESC guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J 32 (2011), 3147–3197.
12. 12 Elkayam, U., Goland, S., Pieper, P.G., Silverside, C.K., High-risk cardiac disease in pregnancy: part I. J Am Coll Cardiol, 2016 In press; http://dx.doi.org/10.1016/j.jacc.2016.05.048.
13. 13 Drenthen, W., Pieper, P.G., Roos-Hesselink, J.W., et al., for the ZAHARA Investigators. Pregnancy and delivery in women after Fontan palliation. Heart 92 (2006), 1290–1294.
14. 14 Gouton, M., Nizard, J., Patel, M., et al. Maternal and fetal outcomes of pregnancy with Fontan circulation: a multicentric observational study. Int J Cardiol 187 (2015), 84–89.
15. 15 Swan, L., Congenital heart disease in pregnancy. Best Pract Res Clin Obstet Gynaecol 28 (2014), 495–506.
16. 16 Greutmann, M., Pieper, P.G., Pregnancy in women with congenital heart disease. Eur Heart J 36 (2015), 2491–2499.
17. 17 Jooste, E.H., Haft, W.A., Ames, W.A., et al. Anesthetic care of parturients with single ventricle physiology. J Clin Anesth 25 (2013), 417–423.
18. 18 Cataldo, S., Doohan, M., Rice, K., et al. Pregnancy following Mustard or Senning correction of transposition of the great arteries: a retrospective study. BJOG 123 (2016), 807–813.
19. 19 Drenthen, W., Pieper, P.G., Ploeg, M., et al., for the ZAHARA Investigators. Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. Eur Heart J 26 (2005), 2588–2595.
20. 20 Gelson, E., Curry, R., Gatzoulis, M.A., et al. Pregnancy in women with a systemic right ventricle after surgically and congenitally corrected transposition of the great arteries. Eur J Obstet Gynecol Reprod Biol 155 (2011), 146–149.
21. 21 Guédès, A., Mercier, L.A., Leduc, L., et al. Impact of pregnancy on the systemic right ventricle after a Mustard operation for transposition of the great arteries. J Am Coll Cardiol 44 (2004), 433–437.
22. 22 Metz, T.D., Jackson, G.M., Yetman, A.T., Pregnancy outcomes in women who have undergone an atrial switch repair for congenital d-transposition of the great arteries. Am J Obstet Gynecol 205 (2011), 273.e1–273.e5.
23. 23 Trigas, V., Nagdyman, N., Pildner von Steinburg, S., et al. Pregnancy-related obstetric and cardiologic problems in women after atrial switch operation for transposition of the great arteries. Circ J 78 (2014), 443–449.
24. 24 Zentner, D., Wheeler, M., Grigg, L., Does pregnancy contribute to systemic right ventricular dysfunction in adults with an atrial switch operation?. Heart Lung Circ 21 (2012), 433–438.
25. 25 Connolly, H.M., Grogan, M., Warnes, C.A., Pregnancy among women with congenitally corrected transposition of great arteries. J Am Coll Cardiol 33 (1999), 1692–1695.
26. 26 Kowalik, E., Klisiewicz, A., Biernacka, E.K., et al. Pregnancy and long-term cardiovascular outcomes in women with congenitally corrected transposition of the great arteries. Int J Gynaecol Obstet 125 (2014), 154–157.
27. 27 Presbitero, P., Somerville, J., Stone, S., et al. Pregnancy in cyanotic congenital heart disease. Outcome of mother and fetus. Circulation 89 (1994), 2673–2676.
28. 28 Neumayer, U., Somerville, J., Outcome of pregnancies in patients with complex pulmonary atresia. Heart 78 (1997), 16–21.
29. 29 Galie, N., Humbert, M., Vachiery, J.L., et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 37 (2016), 67–119.
30. 30 Pieper, P.G., Lameijer, H., Hoendermis, E.S., Pregnancy and pulmonary hypertension. Best Pract Res Clin Obstet Gynaecol 28 (2014), 579–591.
31. 31 Weiss, B.M., Zemp, L., Seifert, B., et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 31 (1998), 1650–1657.
32. 32 Bédard, E., Dimopoulos, K., Gatzoulis, M.A., Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?. Eur Heart J 30 (2009), 256–265.
33. 33 Katsuragi, S., Yamanaka, K., Neki, R., et al. Maternal outcome in pregnancy complicated with pulmonary arterial hypertension. Circ J 76 (2012), 2249–2254.
34. 34 Subbaiah, M., Kumar, S., Roy, K.K., et al. Pregnancy outcome in women with pulmonary arterial hypertension: single-center experience from India. Arch Gynecol Obstet 288 (2013), 305–309.
35. 35 Kiely, D.G., Condliffe, R., Webster, V., et al. Improved survival in pregnancy and pulmonary hypertension using a multiprofessional approach. BJOG 117 (2010), 565–574.
36. 36 Jaïs, X., Olsson, K.M., Barbera, J.A., et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J 40 (2012), 881–885.
37. 37 Judge, D.P., Dietz, H.C., Marfan's syndrome. Lancet 366 (2005), 1965–1976.
38. 38 Ho, N.C., Tran, J.R., Bektas, A., Marfan's syndrome. Lancet 366 (2005), 1978–1981.
39. 39 von Kodolitsch, Y., Robinson, P.N., Marfan syndrome: an update of genetics, medical and surgical management. Heart 93 (2007), 755–760.
40. 40 De Paepe, A., Devereux, R.B., Dietz, H.C., et al. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 62 (1996), 417–426.
41. 41 Summers, K.M., West, J.A., Peterson, M.M., et al. Challenges in the diagnosis of Marfan syndrome. Med J Aust 184 (2006), 627–631.
42. 42 Elkayam, U., Ostrzega, E., Shotan, A., et al. Cardiovascular problems in pregnant women with the Marfan syndrome. Ann Intern Med 123 (1995), 117–122.
43. 43 Pyeritz, R.E., Maternal and fetal complications of pregnancy in the Marfan syndrome. Am J Med 71 (1981), 784–790.
44. 44 Immer, F.F., Bansi, A.G., Immer-Bansi, A.S., et al. Aortic dissection in pregnancy: analysis of risk factors and outcome. Ann Thorac Surg 76 (2003), 309–314.
45. 45 Goland, S., Barakat, M., Khatri, N., et al. Pregnancy in Marfan syndrome: maternal and fetal risk and recommendations for patient assessment and management. Cardiol Rev 17 (2009), 253–262.
46. 46 Rossiter, J.P., Repke, J.T., Morales, A.J., et al. A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. Am J Obstet Gynecol 173 (1995), 1599–1606.
47. 47 Lipscomb, K.J., Smith, J.C., Clarke, B., et al. Outcome of pregnancy in women with Marfan's syndrome. BJOG 104 (1997), 201–206.
48. 48 Lind, J., Wallenburg, H.C., The Marfan syndrome and pregnancy: a retrospective study in a Dutch population. Eur J Obstet Gynecol Reprod Biol 98 (2001), 28–35.
49. 49 Meijboom, L.J., Timmermans, J., Zwinderman, A.H., et al. Aortic root growth in men and women with the Marfan's syndrome. Am J Cardiol 96 (2005), 1441–1444.
50. 50 Donnelly, R.T., Pinto, N.M., Kocolas, I., et al. The immediate and long-term impact of pregnancy on aortic growth rate and mortality in women with Marfan syndrome. J Am Coll Cardiol 60 (2012), 224–229.
51. 51 Meijboom, L.J., Drenthen, W., Pieper, P.G., et al., for the ZAHARA Investigators. Obstetric complications in Marfan syndrome. Int J Cardiol 110 (2006), 53–59.
52. 52 Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 24 (2003), 761–781.
53. 53 Goland, S., Elkayam, U., Cardiovascular problems in pregnant women with Marfan syndrome. Circulation 119 (2009), 619–623.
54. 54 Eldadah, Z.A., Grifo, J.A., Dietz, H.C., Marfan syndrome as a paradigm for transcript-targeted preimplantation diagnosis of heterozygous mutations. Nat Med 1 (1995), 798–803.
55. 55 den Hartog, A.W., Franken, R., Zwinderman, A.H., et al. The risk for type B aortic dissection in Marfan syndrome. J Am Coll Cardiol 65 (2015), 246–254.
56. 56 Hiratzka, L.F., Bakris, G.L., Beckman, J.A., et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease. J Am Coll Cardiol 55 (2010), e27–e129.
57. 57 Zeebregts, C.J., Schepens, M.A., Hameeteman, T.M., et al. Acute aortic dissection complicating pregnancy. Ann Thorac Surg 64 (1997), 1345–1348.
58. 58 Weiss, B.M., von Segesser, L.K., Alon, E., et al. Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984–1996. Am J Obstet Gynecol 179 (1998), 1643–1653.
59. 59 Keane, M.G., Pyeritz, R.E., Medical management of Marfan syndrome. Circulation 117 (2008), 2802–2813.
60. 60 Krishnamoorthy, P., Garg, J., Shah, N., Sharma, A., Jacobs, L., Martinez, M., Effect of beta-blockers on progressive aortic dilatation in patients with Marfan's syndrome (abstr). J Am Coll Cardiol, 65(Suppl 10S), 2015, A2106.
61. 61 Matura, L.A., Ho, V.B., Rosing, D.R., et al. Aortic dilatation and dissection in Turner syndrome. Circulation 116 (2007), 1663–1670.
62. 62 Gravholt, C.H., Landin-Wilhelmsen, K., Stochholm, K., et al. Clinical and epidemiological description of aortic dissection in Turner's syndrome. Cardiol Young 16 (2006), 430–436.
63. 63 Carlson, M., Silberbach, M., Dissection of the aorta in Turner syndrome: two cases and review of 85 cases in the literature. J Med Genet 44 (2007), 745–749.
64. 64 Bondy, C.A., Aortic dissection in Turner syndrome. Curr Opin Cardiol 23 (2008), 519–526.
65. 65 Karnis, M.F., Zimon, A.E., Lalwani, S.I., et al. Risk of death in pregnancy achieved through oocyte donation in patients with Turner syndrome: a national survey. Fertil Steril 80 (2003), 498–501.
66. 66 Carlson, M., Airhart, N., Lopez, L., et al. Moderate aortic enlargement and bicuspid aortic valve are associated with aortic dissection in Turner syndrome: report of the International Turner Syndrome Aortic Dissection Registry. Circulation 126 (2012), 2220–2226.
67. 67 Wong, S.C., Cheung, M., Zacharin, M., Aortic dilatation and dissection in Turner syndrome: what we know, what we are unclear about and what we should do in clinical practice?. Int J Adolesc Med Health 26 (2014), 469–488.
68. 68 Nienaber, C.A., Fattori, R., Mehta, R.H., et al., for the International Registry of Acute Aortic Dissection. Gender-related differences in acute aortic dissection. Circulation 109 (2004), 3014–3021.
69. 69 McKellar, S.H., MacDonald, R.J., Michelena, H.I., et al. Frequency of cardiovascular events in women with a congenitally bicuspid aortic valve in a single community and effect of pregnancy on events. Am J Cardiol 107 (2011), 96–99.
70. 70 Itagaki, S., Chikwe, J.P., Chiang, Y.P., et al. Long-term risk for aortic complications after aortic valve replacement in patients with bicuspid aortic valve versus Marfan syndrome. J Am Coll Cardiol 65 (2015), 2363–2369.
71. 71 Baumgartner, H., Bonhoeffer, P., De Groot, N.M., et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 31 (2010), 2915–2957.
72. 72 Elliott, P., Cardiomyopathy. Diagnosis and management of dilated cardiomyopathy. Heart 84 (2000), 106–112.
73. 73 Pearson, G.D., Veille, J.C., Rahimtoola, S., et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 283 (2000), 1183–1188.
74. 74 Elkayam, U., Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 58 (2011), 659–670.
75. 75 Sliwa, K., Fett, J., Elkayam, U., Peripartum cardiomyopathy. Lancet 368 (2006), 687–693.
76. 76 Fett, J.D., Christie, L.G., Carraway, R.D., et al. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 80 (2005), 1602–1606.
77. 77 Brar, S.S., Khan, S.S., Sandhu, G.K., et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 100 (2007), 302–304.
78. 78 Sliwa, K., Hilfiker-Kleiner, D., Petrie, M.C., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 12 (2010), 767–778.
79. 79 Elkayam, U., Akhter, M.W., Singh, H., et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 111 (2005), 2050–2055.
80. 80 Kolte, D., Khera, S., Aronow, W.S., et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc, 3, 2014, e001056.
81. 81 van Spaendonck-Zwarts, K.Y., van Tintelen, J.P., van Veldhuisen, D.J., et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 121 (2010), 2169–2175.
82. 82 Morales, A., Painter, T., Li, R., et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 121 (2010), 2176–2182.
83. 83 Goland, S., Modi, K., Bitar, F., et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 15 (2009), 645–650.
84. 84 Gentry, M.B., Dias, J.K., Luis, A., et al. African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol 55 (2010), 654–659.
85. 85 Liu, L.X., Arany, Z., Maternal cardiac metabolism in pregnancy. Cardiovasc Res 101 (2014), 545–553.
86. 86 Hilfiker-Kleiner, D., Kaminski, K., Podewski, E., et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 (2007), 589–600.
87. 87 Patten, I.S., Rana, S., Shahul, S., et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485 (2012), 333–338.
88. 88 Powe, C.E., Levine, R.J., Karumanchi, S.A., Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 123 (2011), 2856–2869.
89. 89 Bello, N., Rendon, I.S., Arany, Z., The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. J Am Coll Cardiol 62 (2013), 1715–1723.
90. 90 Haghikia, A., Podewski, E., Libhaber, E., et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res Cardiol, 108, 2013, 366.
91. 91 Hameed, A.B., Goodwin, T.M., Elkayam, U., Effect of pulmonary stenosis on pregnancy outcomes–a case-control study. Am Heart J 154 (2007), 852–854.
92. 92 Hu, C.L., Li, Y.B., Zou, Y.G., et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart 93 (2007), 488–490.
93. 93 Whitehead, S.J., Berg, C.J., Chang, J., Pregnancy-related mortality due to cardiomyopathy: United States, 1991–1997. Obstet Gynecol 102 (2003), 1326–1331.
94. 94 McNamara, D.M., Elkayam, U., Alharethi, R., et al., for the IPAC Investigators. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol 66 (2015), 905–914.
95. 95 Modi, K.A., Illum, S., Jariatul, K., et al. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol 201 (2009), 171.e1–171.e5.
96. 96 Goland, S., Bitar, F., Modi, K., et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail 17 (2011), 426–430.
97. 97 Amos, A.M., Jaber, W.A., Russell, S.D., Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 152 (2006), 509–513.
98. 98 Fett, J.D., Sannon, H., Thélisma, E., et al. Recovery from severe heart failure following peripartum cardiomyopathy. Int J Gynaecol Obstet 104 (2009), 125–127.
99. 99 Blauwet, L.A., Libhaber, E., Forster, O., et al. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart 99 (2013), 308–313.
100. 100 Elkayam, U., Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol 64 (2014), 1629–1636.
101. 101 Elkayam, U., Tummala, P.P., Rao, K., et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. [published correction in N Engl J Med 2001;345:552] N Engl J Med 344 (2001), 1567–1571.
102. 102 Fett, J.D., Fristoe, K.L., Welsh, S.N., Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int J Gynaecol Obstet 109 (2010), 34–36.
103. 103 Elkayam, U., Jalnapurkar, S., Barakat, M., Peripartum cardiomyopathy. Cardiol Clin 30 (2012), 435–440.
104. 104 Duncker, D., Haghikia, A., König, T., et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function—value of the wearable cardioverter/defibrillator. Eur J Heart Fail 16 (2014), 1331–1336.
105. 105 Safirstein, J.G., Ro, A.S., Grandhi, S., et al. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol 154 (2012), 27–31.
106. 106 Bozkurt, B., Villaneuva, F.S., Holubkov, R., et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 34 (1999), 177–180.
107. 107 Sliwa, K., Skudicky, D., Candy, G., et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 4 (2002), 305–309.
108. 108 Biteker, M., Duran, N.E., Kaya, H., et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol 100 (2011), 571–577.
109. 109 Sliwa, K., Blauwet, L., Tibazarwa, K., et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 121 (2010), 1465–1473.
110. 110 Felker, G.M., Thompson, R.E., Hare, J.M., et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342 (2000), 1077–1084.
111. 111 Cooper, L.T., Mather, P.J., Alexis, J.D., et al., for the IMAC2 Investigators. Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail 18 (2012), 28–33.
112. 112 Lima, F.V., Parikh, P.B., Zhu, J., et al. Association of cardiomyopathy with adverse cardiac events in pregnant women at the time of delivery. J Am Coll Cardiol HF 3 (2015), 257–266.
113. 113 Bernstein, P.S., Magriples, U., Cardiomyopathy in pregnancy: a retrospective study. Am J Perinatol 18 (2001), 163–168.
114. 114 Avila, W.S., Rossi, E.G., Ramires, J.A., et al. Pregnancy in patients with heart disease: experience with 1,000 cases. Clin Cardiol 26 (2003), 135–142.
115. 115 Grewal, J., Siu, S.C., Ross, H.J., et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 55 (2009), 45–52.